Business Context and Reporting Period
The filing is Aeglea BioTherapeutics, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2018. The request metadata identifies Spyre Therapeutics, Inc., but the filing itself identifies Aeglea BioTherapeutics, Inc. as the registrant.
Aeglea is a clinical-stage biotechnology company developing engineered human enzyme therapeutics for rare genetic diseases and cancer. Its lead candidate, pegzilarginase, was being evaluated in clinical trials for Arginase 1 Deficiency, advanced solid tumors, and in combination with pembrolizumab for small cell lung cancer. The company had no approved products and no product revenue.
Key Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Grant revenue | $0.0 million, versus $1.3 million | $3.9 million, versus $3.7 million |
| Research and development expense | $8.9 million, versus $6.2 million | $24.9 million, versus $17.0 million |
| General and administrative expense | $3.3 million, versus $3.0 million | $9.1 million, versus $7.7 million |
| Loss from operations | $(12.2) million, versus $(8.0) million | $(30.2) million, versus $(21.1) million |
| Net loss | $(11.9) million, versus $(7.9) million | $(29.5) million, versus $(20.8) million |
| Net loss per share | $(0.54), versus $(0.48) | $(1.49), versus $(1.42) |
| Cash used in operating activities | Not presented quarterly | $(25.0) million, versus $(18.7) million |
Operating expenses increased 32% in the quarter and 37% for the nine-month period. Operating and net-loss margins are not meaningful because revenue consisted solely of grant reimbursements and the company had no product sales. Stock-based compensation was $2.9 million for the nine months, up from $1.8 million.
Cash, Liquidity, Debt and Capitalization
- Cash and cash equivalents were $14.5 million at September 30, 2018, compared with $12.8 million at December 31, 2017.
- Marketable securities were $50.2 million, compared with $37.5 million; total cash, cash equivalents and marketable securities were $64.7 million.
- Working capital was $62.9 million and the accumulated deficit was $102.0 million.
- The company reported no debt, credit facility or additional committed capital.
- April 2018 equity offering proceeds were $37.7 million net after discounts, commissions and offering costs.
- In October 2018, after the reporting date, the company sold 1,845,820 shares through its ATM program for $16.4 million net.
- Based on its operating plan, management believed existing liquidity was sufficient to fund operations through approximately the middle of 2020, but stated that additional financing would be needed to execute all planned research and development activities.
Material Changes Versus Prior Comparable Period
- Quarterly grant revenue fell to zero because the $19.8 million CPRIT grant contract ended in May 2018. Nine-month grant revenue increased modestly because additional qualifying clinical costs were incurred before the contract ended.
- Quarterly research and development expense increased $2.7 million, or 43%, primarily from pegzilarginase clinical development, including the Arginase 1 Deficiency, solid-tumor and small-cell-lung-cancer programs.
- Nine-month research and development expense increased $7.9 million, or 46%, while general and administrative expense increased $1.4 million, or 18%, reflecting higher headcount, clinical activity and public-company support costs.
- Nine-month operating cash burn increased by $6.3 million, while financing cash inflows increased to $39.8 million from $11.5 million, primarily due to the April equity offering.
- Common shares outstanding increased to 22.1 million at September 30, 2018 from 16.7 million at December 31, 2017. The filing reported 23.96 million shares outstanding as of November 2, 2018.
Outlook, Commentary, Risks and Unusual Items
- Management expected continued operating losses and increasing research and development spending for the foreseeable future.
- The company reported positive interim clinical observations for pegzilarginase, including reduced arginine levels, reported clinical improvements in some Arginase 1 Deficiency patients and manageable hypersensitivity reactions. These were interim, early-stage observations and were not evidence of regulatory approval or commercial efficacy.
- The filing describes plans to advance AEB4104 for homocystinuria and AEB5100 for cystinuria into IND-enabling studies, with anticipated GLP manufacturing for toxicology studies in the first half of 2019.
- The filing contains inconsistent timing statements regarding the pivotal Arginase 1 Deficiency trial: one section refers to announcing the pivotal design in the fourth quarter of 2019 and initiating the study in the first half of 2019, while other disclosures refer to a fourth-quarter 2018 design announcement. The exact timing should be verified against subsequent filings.
- Key risks include clinical-trial failure or delay, limited patient enrollment, adverse events and immunogenicity, regulatory uncertainty, reliance on third-party manufacturers and CROs, intellectual-property challenges, competition, need for substantial additional financing and potential dilution from future equity offerings.
- The company disclosed serious adverse events in prior or ongoing oncology studies, including deaths, and reported treatment-related hypersensitivity events in the Arginase 1 Deficiency study.
- The CPRIT grant included potential low- to mid-single-digit royalties on future commercialization, declining below 1% after a specified cumulative royalty threshold. The University of Texas license agreements also provide for potential milestone payments of up to $6.4 million and low-single-digit royalties.
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level, with no material changes in internal control over financial reporting during the quarter. No material legal proceedings were reported.
Facts an Investor Should Verify
- Confirm the correct issuer and ticker because the supplied metadata names Spyre Therapeutics while the filing names Aeglea BioTherapeutics.
- Reconcile the reported cash runway through mid-2020 with the increased operating cash burn and the October 2018 ATM financing.
- Review subsequent clinical data for pegzilarginase, particularly durability of benefit, hypersensitivity and anti-drug-antibody rates, and oncology response data.
- Verify the inconsistent pivotal-trial timing disclosures and any changes to the regulatory development plan.
- Assess future financing needs, expected shareholder dilution and the status of the remaining $2.4 million CPRIT grant receivable.
- Review license milestone, royalty and revenue-sharing obligations, as well as third-party manufacturing and supply risks.